论文部分内容阅读
目的探讨恩替卡韦治疗失代偿期乙型肝炎(乙肝)肝硬化的临床疗效。方法 56例失代偿期乙肝肝硬化患者作为本次研究对象,随机分为对照组和观察组,各28例。对照组给予综合性保肝、护肝治疗,观察组在对照组基础上给予恩替卡韦治疗。对两组患者的治疗效果进行比较。结果治疗后,两组乙肝病毒基因(HBV-DNA)、血清丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)均低于治疗前,观察组低于对照组(P<0.05)。观察组HBV-DNA转阴率为57.14%,高于对照组的25.00%(P<0.05)。结论恩替卡韦治疗失代偿期乙肝肝硬化效果显著,可快速抑制病毒复制,值得在临床中推广应用。
Objective To investigate the clinical efficacy of entecavir in the treatment of decompensated hepatitis B (hepatitis B) cirrhosis. Methods Fifty-six patients with decompensated hepatitis B cirrhosis were randomly divided into control group and observation group, with 28 cases in each group. The control group was given comprehensive hepatoprotective and hepatoprotective therapy. The observation group was treated with entecavir on the basis of the control group. The treatment effect of two groups of patients were compared. Results After treatment, the levels of HBV-DNA, ALT and TBIL in both groups were lower than those before treatment and lower in the observation group than those in the control group (P <0.05) . The negative rate of HBV-DNA in the observation group was 57.14%, which was higher than that in the control group (25.00%, P <0.05). Conclusion Entecavir treatment of decompensated hepatitis B cirrhosis significant effect, rapid inhibition of viral replication, it is worth in the clinical application.